Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mohsen Forooghizade"'
Autor:
Fatemeh Gholami, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Akram Ansarifar, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Zahra Taghva, Hooman Bakhshande, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Forooghizade
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity in a phase II trial. Methods We did a phase II, single-centered, randomized, double-blind, placebo-controlled clinical trial of the FAK
Externí odkaz:
https://doaj.org/article/7cff59226f404594bc909b45886fb632
Autor:
Masoud Solaymani-Dodaran, Pouria Basiri, Milad Moradi, Kimiya Gohari, Ali Sheidaei, Mohammadreza Ahi, Farzad Ghafoori Naeeni, Akram Ansarifar, Zahra Rahimi, Fatemeh Gholami, Ahmad Karimi Rahjerdi, Ramin Hamidi Farahani, Kosar Naderi saffar, Soheil Ghasemi, Ali Shooshtari, Mohsen Honari, Ali Mozafari, Samane Khodaverdloo, Mohsen Forooghizadeh
Publikováno v:
Virology Journal, Vol 20, Iss 1, Pp 1-11 (2023)
Abstract Background We compared Fakhravac and BBIBP-Corv2 vaccines in a phase III trial. Method We conducted a multicenter, parallel-group, active-control, non-inferiority clinical trial with pragmatic considerations assessing the safety and efficacy
Externí odkaz:
https://doaj.org/article/5c23619ff3214f14a8dca1f12a65f2d1
Autor:
Mohammadreza Ahi, Ramin Hamidi Farahani, Pouria Basiri, Ahmad Karimi Rahjerdi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Milad Moradi, Farzad Ghafoori Naeeni, Kosar Naderi Saffar, Soheil Ghasemi, Babak Barati, Sohrab Moradi, Arina Monazah, Fatemeh Pouranvari, Mohsen Forooghizadeh
Publikováno v:
Vaccines, Vol 10, Iss 11, p 1800 (2022)
Purpose: This study was completed to assess the immunogenicity and safety of the FAKHRAVAC and BBIBP-CorV vaccines as a booster dose in the population with a history of receiving two doses of BBIBP-CorV vaccine. Methods: In this double-blind, paralle
Externí odkaz:
https://doaj.org/article/7b22729b86374dafb54293d609b7cd6a